提供支持According to VCBeat, Hedu Biomedical (Suzhou) Co., Ltd. ("Hedu Biomedical") has snared tens of millions of yuan (US$1.4 million) in an angel round of financing, led by Mefund Capital. Proceeds of this financing will be used to accelerate the development of the bacterial gene therapy drugs and build a leading biopharmaceutical company at home and abroad.
Established in 2019, Hedu Biomedical is a biopharmaceutical developer and the earliest domestic biopharmaceutical company engaged in the development of gene therapy drugs based on the bacterial carrier. Its business covers biotechnology, genetic technology, technical consulting, R&D, and pharmaceuticals.
At present, Hedu Biomedical keeps carrying out new drug projects in multiple preclinical research stages. At the same time, the company is cooperating with domestic and foreign biological companies to jointly promote the development of several bacterial gene therapy drugs.
Li Shanbing, a partner of Mefund Capital, said, "In recent years, people have paid great attention to the research of intestinal flora, and more than 1,400 clinical trials of intestinal flora have been carried out. Using bacteria as a carrier to deliver gene-based drugs is the latest therapeutic method being tested, which shows great potential. Mefund Capital is very optimistic about the rapid development of Hedu Biomedical in the field of bacterial gene therapy in China."
About Mefund Capital
Founded in 2014 at China's financial hub-Shanghai, Mefund Capital is an investment fund.
The business of Mefund Capital has reached many parts of China, with offices branches established in Beijing, Shenzhen, Zhejiang, Fujian, Shandong, and Jiangxi. Currently, it manages11 investment funds, of which the amount value has reached to nearly 800 million yuan.
Mefund Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments(VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.
渝公网安备 50011202502165号
